The FDA granted approval to Biocon Biologics’ drug Yesafili and Samsung Bioepis and Biogen’s drug Opuviz, the agency announced May 20. The two drugs are biosimilars for Eylea, an injection made by Regeneron that is used to treat wet age-related macular degeneration and other optical conditions.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
